Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
← catalyst calendarNCT05951179 · readout ≤ 1,899 d
Sponsored by Protara Therapeutics (industry) · TARA — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
131estimated
Sites
71
Countries
Argentina, Brazil, Canada +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-15 | actual | When the study began enrolling |
| Primary completion | Oct 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-muscle Invasive Bladder Cancer
Intervention
- Biological: TARA-002
Primary outcome
what the primary-completion date above is the date OFCohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002
measured Month 3 to Month 60
Permalink · TARA's whole pipeline · Catalyst calendar · Every registered study · What changed